Related Experiment Video

Updated: Jun 10, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds

Dan Niculescu-Duvaz1, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk

  • 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

Bioorganic & Medicinal Chemistry
|July 30, 2010
PubMed

Insights

Researchers developed a novel BRAF inhibitor (1j) that effectively targets melanoma. This compound shows nanomolar activity in inhibiting mutant BRAF, blocking ERK activation, and reducing cancer cell proliferation.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Mutations in V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) are frequent in cutaneous melanoma and other cancers.
  • Targeting mutant BRAF is a promising therapeutic strategy for melanoma treatment.

Purpose of the Study:

  • To synthesize and identify novel BRAF inhibitors with enhanced anti-melanoma activity.
  • To evaluate the efficacy of newly synthesized compounds against BRAF-mutant melanoma.

Main Methods:

  • Structure-activity relationship (SAR) studies were performed on an initial triarylimidazole BRAF inhibitor (1a).
  • A series of analogues were synthesized, leading to compound 1j.
  • Compound 1j was tested in vitro for inhibition of purified mutant BRAF activity, inhibition of BRAF-driven extracellular regulated kinase (ERK) activation in melanoma cell lines, and inhibition of cell proliferation.

Main Results:

  • Compound 1j demonstrated nanomolar activity in all three evaluated assays.
  • Specifically, 1j inhibited purified mutant BRAF activity in vitro.
  • 1j effectively inhibited oncogenic BRAF-driven ERK activation and proliferation in BRAF-mutant melanoma cell lines.

Conclusions:

  • Compound 1j represents a potent BRAF inhibitor with significant anti-melanoma potential.
  • The developed inhibitor warrants further investigation for melanoma therapy.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Five-Membered Heterocyclic Aromatic Compounds: Overview01:13

Five-Membered Heterocyclic Aromatic Compounds: Overview

Heterocyclic aromatic compounds are cyclic compounds that are aromatic and have one or more heteroatoms—atoms other than carbon, in the ring. Depending upon the number of atoms present in the ring, they can be either five or six-membered. Examples of five-membered heterocyclic aromatic compounds include pyrrole, furan, thiophene, and imidazole. Pyrrole consists of one nitrogen atom having one lone pair of electrons. Furan and thiophene have one oxygen and one sulfur heteroatom, respectively.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...